MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Zanidip 10mg tablets (Recordati Pharmaceuticals Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Zanidip 20mg tablets (Recordati Pharmaceuticals Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Zanidip 20mg tablets (Recordati Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers. Protect from light.

Provenance

This compatibility recommendation is derived from Solpadol 30mg/500mg capsules (Sanofi), Tylex 30mg/500mg capsules (UCB Pharma Ltd) and generic co-codamol 30mg/500mg capsules.

Stability Notes

Store in airtight containers. Protect from light.

Provenance

This compatibility recommendation is derived from generic co-codamol 30mg/500mg tablets.

Stability Notes

Protect from light. Sensitive to oxygen.

Provenance

This compatibility recommendation is derived from Zaponex 100mg tablets (Leyden Delta B.V.) and Denzapine 100mg tablets (Britannia Pharmaceuticals Ltd).

Stability Notes

Protect from light. Sensitive to oxygen.

Provenance

This compatibility recommendation is derived from Zaponex 25mg tablets (Leyden Delta B.V.) and Denzapine 25mg tablets (Britannia Pharmaceuticals Ltd).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.